Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Miner Is 'Set Up for a Strong 2020'

The numbers from the company's three operations are reviewed in a CIBC report. In a Jan. 12 research note, CIBC analyst Cosmos Chiu reported that Dundee Precious Metals Inc. (DPM:TSX) posted a solid Q4/19 and its production for 2019 fell well within the guidance ran...
Streetwise Reports | January 17, 2020 |

Gold Mountain Signs Ore Purchase Agreement with New Gold

Gold Mountain Mining Corp. ( TSX-V: GMTN , Forum ) is pleased to announce it has signed an Ore Purchase Agreement with New Gold's New Afton Processing facility in Kamloops, BC. With this milestone, we are cash-flow ready once the necessary permits are approved. For...
Stockhouse Editorial | January 27, 2021 |

PCR Testing: XPhyto Disrupts a Blockbuster Business

It’s the technological evolution that could transform the US $84.4 billion Covid-19 diagnostics market. Vancouver-based life sciences company XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) (OTC: XPHYF) expects its rapid Covid-19 test system to be approv...
Marc Davis | February 25, 2021 |

Regeneron Reports Positive Phase 3 Dupixent Data; Gains EU Approval Recommendation

Regeneron Pharmaceuticals published positive results from two U.S. Phase 3 trials evaluating the safety and efficacy of Dupixent (dupilumab) in adults with recurring severe chronic rhinosinusitis with nasal polyps. The European Medicines Agency's Committee for Medicinal Produc...
Streetwise Reports | September 24, 2019 |

Clinical research and tools to address mental health

Our next company is Numinus Wellness Inc. (TSX:NUMI) . Numinus is using the power of psychedelic medicine to make great strides in addressing serious mental health issues. It recently announced its fiscal year 2024 results, which showed strong growth in its busines...
Ryan Dhillon | December 14, 2023 |

Eton Pharma Shares Climb 20% After Firm Secures US Rights for Pediatric Kidney Disease Drug

Shares of Eton Pharmaceuticals traded higher after the company reported that it has acquired U.S. marketing rights to pediatric orphan drug Alkindi® Sprinkle from Diurnal Group Plc. Eton Pharmaceuticals Inc. (ETON:NASDAQ) , which is focused on devel...
Streetwise Reports | March 30, 2020 |

Bayer, Siltronic, XPhyto - is it worthwhile to invest now?

Tuesday began with green lights for most listed companies in Germany. The opinions of analysts and company announcements make the stock prices - or they are driven by the mood of economic data. The Ifo Business Climate Index, for example, rose by 2.2 points to 92.6 points in...
Mario Hose | August 25, 2020 |

Buzz on the Bullboards: Markets struggle in Q1 2023

Despite a solid start to the year, markets on Bay Street and Wall Street have struggled since fresh calendars went up. This week, Canada’s top banks have been pointing to economic pain ahead with higher loan loss provisions and a fall in quarterly prof...
Jonathon Brown | March 2, 2023 |

Sarepta Shares Get a 35% Boost from FDA Approval of 2nd DMD Drug

Sarepta Therapeutics shares traded 35% higher after the firm reported that the FDA approved its second RNA exon-skipping treatment drug VYONDYS 53 injection for the treatment of Duchenne's Muscular Dystrophy in patients amenable to skipping Exon 53. Yesterday evening,...
Streetwise Reports | December 16, 2019 |

Intra-Cellular Therapies Shares Rise 200% on FDA Approval of Adult Schizophrenia Drug

Shares of Intra-Cellular Therapies opened greater than 100% higher today after the company reported that the FDA approved its antipsychotic CAPLYTA® (lumateperone) drug for the treatment of schizophrenia in adults. This morning a biopharmaceutical company foc...
Streetwise Reports | December 27, 2019 |
1 2 3 4 5 6 7 8 9 10 ...